Oral small molecule GLP-1 receptor agonist
Danuglipron 40 mg oral twice daily
DANU_PO_40MG_BID
Related
- All doses pooled: Danuglipron tablet
- Danuglipron 200 mg oral twice daily
- Danuglipron 80 mg oral twice daily
- Danuglipron 140 mg tablet twice daily
- Danuglipron 120 mg oral twice daily
- Danuglipron 160 mg oral twice daily
- Danuglipron 2.5 mg tablet twice daily
- Danuglipron 10 mg tablet twice daily
- Danuglipron 3 mg tablet
- Danuglipron 10 mg tablet
- Danuglipron 30 mg tablet
- Danuglipron 100 mg tablet
- Danuglipron 300 mg tablet
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.70 (0.01 to 56.77) | 0.42 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.31 (0.36 to 32.06) | 0.39 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 5.23 (0.93 to 33.73) | 0.16 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.12 (0.93 to 23.42) | 0.11 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.82 (0.63 to 5.52) | 0.46 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.73 (1.95 to 20.28) | 0.23 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 9.18 (2.20 to 48.78) | 0.18 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.11 (0.94 to 11.77) | 0.25 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 3.27 (0.32 to 37.72) | 0.36 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.52 (0.01 to 23.54) | 0.60 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.87 (0.05 to 13.22) | 0.47 |
Trials
- NCT04707313A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY2021 · 628 randomized · 26 weeks
- NCT03985293A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE2020 · 412 randomized · 16 weeks
- NCT04552470AN 8-WEEK PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TWICE DAILY PF-06882961 ADMINISTRATION IN JAPANESE ADULTS WITH TYPE 2 DIABETES MELLITUS2020 · 37 randomized · 8 weeks